Exagen Diagnostics, Inc. is a Patient Focused, Discovery Driven, CLIA-certified, CAP-accredited laboratory with a growing menu of proprietary, internally developed tests focusing in the area of Rheumatology and Autoimmune diseases. Committed to Personalized Medicine, our tests are specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis and better disease management.
Exagen is the only company to offer cutting-edge Cell-Bound Complement Activation Products (CB-CAPs) technology via the Avise SLE diagnostic. CB-CAPs are hydrolyzed complement activation products bound to circulating cells such as erythrocytes, platelets, B and T lymphocytes. Cell binding confers stability to these markers because they last for the life of the cells. These properties make CB-CAPs ideally suited as biomarkers of SLE.
Even though the technology behind our discoveries may be 'bleeding edge', our marker sets can be implemented using technologies most appropriate for high volume clinical lab use. Marker sets of high potential clinical value can be developed into an assay suited for the intended application, whether that be disease diagnosis, prognosis, susceptibility, or prediction of likely treatment response.
Exagen is committed to translating our discovery and development into real solutions that are safe, reliable and cost effective.